[
  {
    "EudraCT Number:": "2020-002476-13",
    "Sponsor Protocol Number:": "20HH5958",
    "Sponsor Name:": "Imperial College London",
    "Full Title:": "A study to assess the safety and efficacy of Clazakizumab in patients with COVID-19 and kidney disease. ",
    "Start Date:": "2020-07-24",
    "Medical condition:": "Patients with kidney disease who are hospitalised with COVID-19 infection with pulmonary involvement (i.e. consistent chest imaging abnormalities) and clinical deterioration (i.e increasing oxygen ...",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004857, Classification Code: 10023417, Term: Kidney dysfunction, Level: LLT",
    "Disease 2:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10047463, Term: Viral infection NOS, Level: LLT",
    "Disease 3:": "Version: 20.0, SOC Term: 10022891 - Investigations, Classification Code: 10063321, Term: Interleukin level, Level: PT",
    "Disease 4:": "Version: 20.1, SOC Term: 10041244 - Social circumstances, Classification Code: 10079637, Term: Dependence on oxygen therapy, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002476-13"
  },
  {
    "EudraCT Number:": "2020-004144-28",
    "Sponsor Protocol Number:": "CCTU0307",
    "Sponsor Name:": "Cambridge university Hosptials NHS Foundation Trust and University of Cambridge",
    "Full Title:": "PROphylaxis for paTiEnts at risk of COVID-19 infecTion",
    "Start Date:": "2020-10-23",
    "Medical condition:": "",
    "Population Age:": "",
    "Gender:": "",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004144-28",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-004994-27",
    "Sponsor Protocol Number:": "2020SW03",
    "Sponsor Name:": "Ashford and St Peter's Hospitals NHS Foundation Trust",
    "Full Title:": "Clinical Efficacy of Nitric Oxide Nasal Spray (NONS) for the Treatment of Mild COVID-19 Infection",
    "Start Date:": "2020-12-16",
    "Medical condition:": "COVID-19",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004994-27",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001640-26",
    "Sponsor Protocol Number:": "132151",
    "Sponsor Name:": "University College London",
    "Full Title:": "A pilot, open label, phase II clinical trial of nebulised recombinant tissue-Plasminogen Activator (rtPA)in patients with COVID-19 ARDS: The Plasminogen Activator COVID-19 ARDS (PACA) trial  ",
    "Start Date:": "2020-04-17",
    "Medical condition:": "Acute respiratory distress syndrome (ARDS) caused by COVID-19 ",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001640-26",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001805-21",
    "Sponsor Protocol Number:": "RA486120",
    "Sponsor Name:": "University Hospital Coventry & Warwickshire",
    "Full Title:": "Prospective, Randomized, Parallel-Group, Open-Label Study to Evaluate the Efficacy and Safety of IMU-838, in Combination with Oseltamivir, in Adults with Coronavirus Disease COVID-19 ",
    "Start Date:": "2020-05-15",
    "Medical condition:": "Sars-Cov-2",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001805-21",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001228-32",
    "Sponsor Protocol Number:": "COV002",
    "Sponsor Name:": "CTRG",
    "Full Title:": "A phase 2/3 study to determine the efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19",
    "Start Date:": "2020-05-04",
    "Medical condition:": "SARS-CoV-2",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001228-32"
  },
  {
    "EudraCT Number:": "2020-001449-38",
    "Sponsor Protocol Number:": "CW002",
    "Sponsor Name:": "Chelsea and Westminster Hospital NHS Foundation Trust",
    "Full Title:": "A Randomised Controlled Trial of Early Intervention in Patients HospItalised with COVID-19: Favipiravir verses HydroxycholorquiNe & Azithromycin & Zinc vErsEs Standard CaRe ",
    "Start Date:": "2020-04-29",
    "Medical condition:": "COVID-19 Infection",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10051905, Term: Coronavirus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001449-38"
  },
  {
    "EudraCT Number:": "2020-002567-57",
    "Sponsor Protocol Number:": "1.0",
    "Sponsor Name:": "University of Oxford / Clinical Trials and Research Governance",
    "Full Title:": "To determine whether administration of almitrine bismesylate can ameliorate hypoxaemia in Covid-19 and augment effectiveness of supplementary oxygen therapy and respiratory support",
    "Start Date:": "2020-11-23",
    "Medical condition:": "Covid-19",
    "Disease 1:": "Version: 21.1, SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders, Classification Code: 10001053, Term: Acute respiratory failure, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002567-57"
  },
  {
    "EudraCT Number:": "2020-002668-29",
    "Sponsor Protocol Number:": "132796",
    "Sponsor Name:": "University College London",
    "Full Title:": "A Randomised Controlled Trial of plasma exchange with standard of care compared to standard of care alone in the treatment of severe COVID-19 infection (COVIPLEX)  ",
    "Start Date:": "2020-06-25",
    "Medical condition:": "COVID-19",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002668-29",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001996-33",
    "Sponsor Protocol Number:": "CD12_COVID-19",
    "Sponsor Name:": "CytoDyn, Inc.",
    "Full Title:": "A Phase 2b/3, Randomized, Double Blind, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (CO...",
    "Start Date:": "2020-08-26",
    "Medical condition:": "Coronavirus Disease 2019 (COVID-19)",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001996-33"
  },
  {
    "EudraCT Number:": "2020-002106-68",
    "Sponsor Protocol Number:": "CTU/2020/354",
    "Sponsor Name:": "University College London Comprehensive Clinical Trial Unit",
    "Full Title:": "Favipiravir, lopinavir/ritonavir or combination therapy: a randomised, double blind, 2x2 factorial placebo-controlled trial of early antiviral therapy in COVID-19",
    "Start Date:": "2020-07-16",
    "Medical condition:": "SARS-CoV-2 (Corona virus) infection",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002106-68"
  },
  {
    "EudraCT Number:": "2020-001643-13",
    "Sponsor Protocol Number:": "01.01.20",
    "Sponsor Name:": "University of Dundee",
    "Full Title:": "A randomised double-blind placebo-controlled trial of Brensocatib (INS1007) in patients with severe COVID-19 ",
    "Start Date:": "2020-05-15",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001643-13"
  },
  {
    "EudraCT Number:": "2020-002230-32",
    "Sponsor Protocol Number:": "",
    "Sponsor Name:": "University of Edinburgh",
    "Full Title:": "Rapid Experimental Medicine for COVID-19 ",
    "Start Date:": "2020-06-23",
    "Medical condition:": "COVID-19",
    "Population Age:": "Under 18, Adults",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002230-32",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001636-95",
    "Sponsor Protocol Number:": "282110",
    "Sponsor Name:": "University of Manchester",
    "Full Title:": "Subcutaneous and Intravenous anakinra in COVID-19 Infection -  Feasibility & Pharmacokinetics/ Pharmacodynamics study",
    "Start Date:": "2020-05-20",
    "Medical condition:": "Suspected or confirmed SARS-CoV-2 infection (confirmed by RNA-PCR)",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001636-95"
  },
  {
    "EudraCT Number:": "2020-002229-27",
    "Sponsor Protocol Number:": "TACTIC-E",
    "Sponsor Name:": "Cambridge University Hospitals NHS Foundation Trust",
    "Full Title:": "mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 \u2013 Experimental drugs and mechanisms  ",
    "Start Date:": "2020-06-09",
    "Medical condition:": "SARS-Cov-2",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002229-27",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001023-14",
    "Sponsor Protocol Number:": "SG016",
    "Sponsor Name:": "Synairgen Research Limited",
    "Full Title:": "A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFN\u03b2-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infectio...",
    "Start Date:": "2020-03-17",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10051905, Term: Coronavirus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001023-14"
  },
  {
    "EudraCT Number:": "2020-004719-28",
    "Sponsor Protocol Number:": "D8850C00003",
    "Sponsor Name:": "AstraZeneca AB",
    "Full Title:": "A Phase III Randomized, Double-blind, Placebo-controlled, Multi-center Study in Adults to Determine the Safety and Efficacy of AZD7442, a Combination Product of Two Monoclonal Antibodies (AZD8895 a...",
    "Start Date:": "2020-11-20",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-004719-28"
  },
  {
    "EudraCT Number:": "2020-001786-36",
    "Sponsor Protocol Number:": "ILIAD-7-UK-Cohort",
    "Sponsor Name:": "RevImmune SAS France",
    "Full Title:": "Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection \u201cILIAD 7 trial\u201d",
    "Start Date:": "2020-05-06",
    "Medical condition:": "Lymphopenia and T cell exhaustion in  COVID-19 patients",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001786-36",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001354-22",
    "Sponsor Protocol Number:": "TACTIC-R",
    "Sponsor Name:": "Cambridge University Hospitals NHS Foundation Trust",
    "Full Title:": "Multiarm Therapeutic study in pre-ICU patients admitted with COVID-19 - Repurposed Drugs (TACTIC-R)",
    "Start Date:": "2020-05-06",
    "Medical condition:": "COVID-19-related complications",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001354-22",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001473-79",
    "Sponsor Protocol Number:": "ESR-20-20653",
    "Sponsor Name:": "Saint Luke\u2019s Hospital of Kansas City, Kansas City, Missouri, USA",
    "Full Title:": "An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Phase III Study Evaluating the Efficacy and Safety of Dapagliflozin in Respiratory Failure in Patients with COVID-19",
    "Start Date:": "2020-05-07",
    "Medical condition:": "Respiratory Failure in patients with COVID-19",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001473-79",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001860-27",
    "Sponsor Protocol Number:": "UoL001542",
    "Sponsor Name:": "University of Liverpool",
    "Full Title:": "AGILE: Seamless Phase I/IIa Platform for the Rapid Evaluation of Candidates for COVID-19 treatment",
    "Start Date:": "2020-05-12",
    "Medical condition:": "Coronavirus-induced disease (COVID-19) (SARS coronavirus 2, or SARS-CoV-2)",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001860-27"
  },
  {
    "EudraCT Number:": "2020-001684-89",
    "Sponsor Protocol Number:": "RG_20-030",
    "Sponsor Name:": "University of Birmingham",
    "Full Title:": "CATALYST - A randomised phase II proof of principle multi-arm multi-stage trial designed to guide the selection of interventions for phase III trials in hospitalised patients with COVID-19 infection.",
    "Start Date:": "2020-05-05",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 20.1, SOC Term: 100000004855, Classification Code: 10047468, Term: Viral lower respiratory tract infections, Level: HLT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001684-89"
  },
  {
    "EudraCT Number:": "2020-001203-16",
    "Sponsor Protocol Number:": "LIBERATE",
    "Sponsor Name:": "Guy's and St Thomas' NHS Foundation Trust",
    "Full Title:": "Lipid ibuprofen versus standard of care for acute hypoxaemic respiratory failure due to COVID-19: a multicentre, randomised, controlled trial",
    "Start Date:": "2020-05-06",
    "Medical condition:": "COVID-19\u037e respiratory failure\u037e hypoxaemia.",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Disease 2:": "Version: 21.1, SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders, Classification Code: 10001053, Term: Acute respiratory failure, Level: PT",
    "Disease 3:": "Version: 20.0, SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders, Classification Code: 10021141, Term: Hypoxaemia, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001203-16"
  },
  {
    "EudraCT Number:": "2020-001113-21",
    "Sponsor Protocol Number:": "NDPHRECOVERY",
    "Sponsor Name:": "University of Oxford",
    "Full Title:": "Randomised Evaluation of COVID-19 Therapy (RECOVERY)",
    "Start Date:": "2020-03-17",
    "Medical condition:": "COVID-19 (infection with SARS-CoV-2 virus)",
    "Disease 1:": "Version: 21.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10035737, Term: Pneumonia viral, Level: PT",
    "Disease 2:": "Version: 20.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10061982, Term: Severe acute respiratory syndrome, Level: PT",
    "Population Age:": "Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001113-21"
  },
  {
    "EudraCT Number:": "2020-002952-18",
    "Sponsor Protocol Number:": "Protocol",
    "Sponsor Name:": "Ashford and St Peter's Hospitals NHS Foundation Trust",
    "Full Title:": "Targeting de novo Pyrimidine Biosynthesis by leflunomide as a Novel Concept for the Treatment of Corona Virus Disease 2019 (COVID-19)",
    "Start Date:": "2020-07-21",
    "Medical condition:": "Confirmed Covid-19 infection by RT-PCR",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002952-18",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-000483-27",
    "Sponsor Protocol Number:": "CCT38473",
    "Sponsor Name:": "St.  Joseph\u2019s  Healthcare,  McMaster  University",
    "Full Title:": "Re-Evaluating the Inhibition of Stress Erosions: Gastrointestinal Bleeding Prophylaxis in ICU",
    "Start Date:": "2020-11-19",
    "Medical condition:": "critical illness requiring mechanical ventilation",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-000483-27",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001396-33",
    "Sponsor Protocol Number:": "EPA-COV-001",
    "Sponsor Name:": "SLA Pharma (UK) Ltd",
    "Full Title:": "A randomised, double-blind, placebo-controlled study of eicosapentaenoic acid (EPA-FFA) gastro-resistant capsules to treat hospitalised subjects with confirmed SARS-CoV-2",
    "Start Date:": "2020-11-13",
    "Medical condition:": "SARS-CoV-2",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10084272, Term: SARS-CoV-2 infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001396-33"
  },
  {
    "EudraCT Number:": "2020-002494-10",
    "Sponsor Protocol Number:": "",
    "Sponsor Name:": "Queen Mary University of London",
    "Full Title:": "Personalised Electronic Record Supported OptimisatioN when ALone  for Patients with Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic ",
    "Start Date:": "2020-07-17",
    "Medical condition:": "Hypertension",
    "Disease 1:": "Version: 21.1, SOC Term: 100000004866, Classification Code: 10081425, Term: Arterial hypertension, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002494-10"
  },
  {
    "EudraCT Number:": "2020-001736-95",
    "Sponsor Protocol Number:": "ACCORD-2-001,Sub002,003,006",
    "Sponsor Name:": "University Hospital Southampton NHS Foundation Trust",
    "Full Title:": "ACCORD 2: A Multicentre, Seamless, Phase 2 Adaptive Randomisation Platform Study to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID 19 in Hospitalised Patients ",
    "Start Date:": "2020-04-28",
    "Medical condition:": "COVID 19 ",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001736-95"
  },
  {
    "EudraCT Number:": "2020-003486-19",
    "Sponsor Protocol Number:": "1.002.20",
    "Sponsor Name:": "University of Dundee",
    "Full Title:": "A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in patients with community acquired pneumonia and suspected or con...",
    "Start Date:": "2020-10-08",
    "Medical condition:": "Community acquired pneumonia with suspected or confirmed SARS-CoV-2 infection",
    "Disease 1:": "Version: 20.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10066724, Term: Acute pneumonia, Level: LLT",
    "Disease 2:": "Version: 20.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10010120, Term: Community acquired pneumonia, Level: LLT",
    "Disease 3:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10084380, Term: COVID-19 pneumonia, Level: PT",
    "Disease 4:": "Version: 21.1, SOC Term: 10038738 - Respiratory, thoracic and mediastinal disorders, Classification Code: 10001052, Term: Acute respiratory distress syndrome, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003486-19"
  },
  {
    "EudraCT Number:": "2020-001441-39",
    "Sponsor Protocol Number:": "VIR20001",
    "Sponsor Name:": "University of Oxford",
    "Full Title:": "Chloroquine/ hydroxychloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting; a randomised, placebo-controlled prophylaxis study (COPCOV)",
    "Start Date:": "2020-05-12",
    "Medical condition:": "COVID-19, acute respiratory illness",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) IT(Prematurely Ended) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001441-39"
  },
  {
    "EudraCT Number:": "2020-002503-19",
    "Sponsor Protocol Number:": "62586",
    "Sponsor Name:": "UMC Utrecht",
    "Full Title:": "BCG vaccination to Reduce the impact of COVID-19 in healthcare workers (BRACE) Trial ",
    "Start Date:": "2020-07-08",
    "Medical condition:": "SARS-CoV-2 infection",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004848, Classification Code: 10047490, Term: Virus identification and serology, Level: HLT",
    "Population Age:": "Adults",
    "Gender:": "Male, Female",
    "Trial protocol:": "NL(Completed) GB(GB - no longer in EU/EEA) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002503-19"
  },
  {
    "EudraCT Number:": "2020-001803-17",
    "Sponsor Protocol Number:": "GS-US-540-5823",
    "Sponsor Name:": "Gilead Sciences Inc.",
    "Full Title:": "A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734\u2122) in Participants from Birth to < 18 Years of Age with COVID-19",
    "Start Date:": "2020-07-14",
    "Medical condition:": "Coronavirus disease 2019 (COVID-19)",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Newborns, Infants and toddlers, Children, Adolescents, Under 18",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) IT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001803-17"
  },
  {
    "EudraCT Number:": "2020-003643-29",
    "Sponsor Protocol Number:": "VAC31518COV3009",
    "Sponsor Name:": "Janssen Vaccines & Prevention B.V.  ",
    "Full Title:": "A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older  E...",
    "Start Date:": "2020-11-10",
    "Medical condition:": "Healthy Volunteers, with or without comorbidities (Prevention of SARS-CoV-2-mediated COVID-19)",
    "Disease 1:": "Version: 23.1, SOC Term: 100000004865, Classification Code: 10084465, Term: COVID-19 vaccination, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) FR(Ongoing) DE(Ongoing) ES(Temporarily Halted) BE(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003643-29"
  },
  {
    "EudraCT Number:": "2020-002211-21",
    "Sponsor Protocol Number:": "SGS.1656.201",
    "Sponsor Name:": "St George Street Capital Ltd",
    "Full Title:": "A Phase II, randomised, double-blind, placebo-controlled clinical trial to assess the safety and efficacy of AZD1656 in diabetic patients hospitalised with suspected or confirmed COVID-19. The ARCA...",
    "Start Date:": "2020-07-31",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10084382, Term: Coronavirus disease 2019, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) CZ(Completed) RO(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002211-21"
  },
  {
    "EudraCT Number:": "2020-002542-16",
    "Sponsor Protocol Number:": "INSIGHT013",
    "Sponsor Name:": "Office of Sponsored Projects, Regents of the University of Minnesota",
    "Full Title:": "An International Multicenter, Adaptive, Randomized Double-Blind, Placebo-Controlled Trial of the Safety, Tolerability and Efficacy of Anti-Coronavirus Hyperimmune Intravenous Immunoglobulin for the...",
    "Start Date:": "2020-09-30",
    "Medical condition:": "COVID-19 (SARS-CoV-2) infection",
    "Disease 1:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10051905, Term: Coronavirus infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) GR(Completed) DK(Completed) DE(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-002542-16"
  },
  {
    "EudraCT Number:": "2020-003125-39",
    "Sponsor Protocol Number:": "TRI-08892",
    "Sponsor Name:": "Thrombosis Research Institute",
    "Full Title:": "Early thromboprophylaxis in COVID-19 (ETHIC trial): an open label, randomized phase IIIb trial of community-based prophylactic low-molecular-weight heparin (LMWH) versus standard of care (no enoxap...",
    "Start Date:": "2020-10-12",
    "Medical condition:": "Confirmed diagnosis of SARS-CoV-2  with symptomatic COVID-19 infection ",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "BE(Completed) GB(GB - no longer in EU/EEA) DE(Prematurely Ended) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003125-39",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001497-30",
    "Sponsor Protocol Number:": "ALXN1210-COV-305",
    "Sponsor Name:": "Alexion Pharmaceuticals, Inc.",
    "Full Title:": "COVID-19 A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-1...",
    "Start Date:": "2020-05-07",
    "Medical condition:": "COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome",
    "Disease 1:": "Version: 20.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10061229, Term: Lung infection, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) FR(Prematurely Ended) DE(Prematurely Ended) ES(Prematurely Ended) IT(Prematurely Ended) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001497-30"
  },
  {
    "EudraCT Number:": "2020-003368-24",
    "Sponsor Protocol Number:": "MK-4482-002",
    "Sponsor Name:": "Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.",
    "Full Title:": "A Phase 2/3, Randomized, Placebo-Controlled, Double-Blind Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of MK-4482 in Non-Hospitalized Adults with COVID-19",
    "Start Date:": "2020-11-18",
    "Medical condition:": "COVID-19",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10084382, Term: Coronavirus disease 2019, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "FR(Completed) GB(GB - no longer in EU/EEA) DE(Completed) IT(Completed) PL(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-003368-24"
  },
  {
    "EudraCT Number:": "2020-001689-12",
    "Sponsor Protocol Number:": "MHIPS-2020-001",
    "Sponsor Name:": "MONTREAL HEART INSTITUTE",
    "Full Title:": "COLCHICINA TEST IN THE SARS-COV2 CORONAVIRUS (COLCORONA-COVID-19)",
    "Start Date:": "2020-04-11",
    "Medical condition:": "Men and women over 40 years of age, with a diagnosis of COVID-19 infection and at least one high risk criterion.",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "ES(Ongoing) GB(GB - no longer in EU/EEA) FR(Prematurely Ended) GR(Prematurely Ended) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001689-12Request failed.",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2020-001759-42",
    "Sponsor Protocol Number:": "214094",
    "Sponsor Name:": "GlaxoSmithKline Research & Development Limited",
    "Full Title:": "A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.",
    "Start Date:": "2020-05-20",
    "Medical condition:": "Severe pulmonary COVID-19 related disease",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) NL(Completed) ES(Completed) BE(Completed) DE(Completed) IT(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001759-42"
  },
  {
    "EudraCT Number:": "2018-003898-94",
    "Sponsor Protocol Number:": "BN40955",
    "Sponsor Name:": "F.Hoffmann La-Roche Ltd",
    "Full Title:": "AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLERABILITY OF INTRATHECALLY ADMINISTERED RO7234292 (RG6042) IN PATIENTS WITH HUNTINGTON\u2019S DISEASE ",
    "Start Date:": "2019-03-07",
    "Medical condition:": "Huntington's disease (HD)",
    "Disease 1:": "Version: 20.0, SOC Term: 10010331 - Congenital, familial and genetic disorders, Classification Code: 10070668, Term: Huntington's disease, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ES(Temporarily Halted) NL(Completed) AT(Completed) IT(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-003898-94"
  },
  {
    "EudraCT Number:": "2017-004958-42",
    "Sponsor Protocol Number:": "MOM-M281-003",
    "Sponsor Name:": "Momenta Pharmaceuticals, Inc.",
    "Full Title:": "A Multicenter, Open-Label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease ...",
    "Start Date:": "2019-01-11",
    "Medical condition:": "Early onset Severe Hemolytic Disease of the fetus and newborn (HDFN)",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004850, Classification Code: 10019512, Term: Hemolytic disease due to Rh isoimmunization of fetus or newborn, Level: LLT",
    "Population Age:": "In utero, Under 18, Adults",
    "Gender:": "Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) BE(Ongoing) NL(Ongoing) SE(Ongoing) ES(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004958-42"
  },
  {
    "EudraCT Number:": "2020-001370-30",
    "Sponsor Protocol Number:": "CACZ885D2310",
    "Sponsor Name:": "Novartis Pharma AG",
    "Full Title:": "Phase 3 multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab on cytokine release syndrome in patients with COVID-19-induced pneumonia (CA...",
    "Start Date:": "2020-04-29",
    "Medical condition:": "COVID-19-induced pneumonia (CAN-COVID)",
    "Disease 1:": "Version: 23.0, SOC Term: 100000004862, Classification Code: 10053983, Term: Corona virus infection, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DE(Completed) GB(GB - no longer in EU/EEA) FR(Completed) ES(Completed) HU(Completed) IT(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001370-30"
  },
  {
    "EudraCT Number:": "2018-000930-37",
    "Sponsor Protocol Number:": "M15-722",
    "Sponsor Name:": "AbbVie Deutschland GmbH & Co. KG",
    "Full Title:": "A Multicenter, Single-Arm, Open-Label Study to Investigate the Efficacy and Safety of Ravagalimab (ABBV-323) in Subjects with Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy",
    "Start Date:": "2018-12-21",
    "Medical condition:": "Ulcerative Colitis",
    "Disease 1:": "Version: 20.1, SOC Term: 100000004856, Classification Code: 10045365, Term: Ulcerative colitis, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "NL(Prematurely Ended) DE(Prematurely Ended) GB(GB - no longer in EU/EEA) FR(Prematurely Ended) ES(Completed) HU(Completed) IT(Prematurely Ended) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-000930-37"
  },
  {
    "EudraCT Number:": "2015-002340-14",
    "Sponsor Protocol Number:": "REMAP-CAP",
    "Sponsor Name:": "University Medical Center Utrecht ",
    "Full Title:": "Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP). (COVID-19)",
    "Start Date:": "2015-09-16",
    "Medical condition:": "Severe Community Acquired Pneumonia",
    "Disease 1:": "Version: 20.1, SOC Term: 10021881 - Infections and infestations, Classification Code: 10010120, Term: Community acquired pneumonia, Level: LLT",
    "Disease 2:": "Version: 23.0, SOC Term: 10021881 - Infections and infestations, Classification Code: 10084268, Term: COVID-19, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "NL(Ongoing) IE(Ongoing) PT(Ongoing) GB(GB - no longer in EU/EEA) HU(Ongoing) BE(Ongoing) DE(Ongoing) HR(Ongoing) ES(Temporarily Halted) FR(Ongoing) FI(Ongoing) IT(Ongoing) SI(Ongoing) RO(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-002340-14",
    "COVID-19": ""
  },
  {
    "EudraCT Number:": "2017-001365-24",
    "Sponsor Protocol Number:": "WN39658",
    "Sponsor Name:": "Roche Farma S.A.(Soc. Unipersonal) que realiza el ensayo en Espa\u00f1a y act\u00faa como representante de F.Hoffmann-La Roche LTD",
    "Full Title:": "A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, AND SAFETY STUDY OF GANTENERUMAB IN PATIENTS WITH EARLY (PRODROMAL TO MILD) ALZHEIMER\u2019S DISEASE",
    "Start Date:": "2018-06-05",
    "Medical condition:": "Alzheimer\u2019s Disease (AD)",
    "Disease 1:": "Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10001897, Term: Alzheimer's disease (incl subtypes), Level: HLT",
    "Disease 2:": "Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10074616, Term: Prodromal Alzheimer's disease, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "ES(Ongoing) GB(GB - no longer in EU/EEA) DK(Ongoing) BE(Completed) PT(Ongoing) PL(Prematurely Ended) NL(Prematurely Ended) SE(Completed) FI(Prematurely Ended) HR(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-001365-24"
  },
  {
    "EudraCT Number:": "2019-000954-67",
    "Sponsor Protocol Number:": "ATB200-07",
    "Sponsor Name:": "Amicus Therapeutics, Inc.",
    "Full Title:": "A Phase 3 Open-label Extension Study to Assess the Long-term Safety and Efficacy of Intravenous ATB200 Co-administered With Oral AT2221 in Adult Subjects With Late-onset Pompe Disease",
    "Start Date:": "2020-04-08",
    "Medical condition:": "Adult Subjects With Late Onset Pompe Disease (LOPD)",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004850, Classification Code: 10075702, Term: Pompe's disease late onset, Level: LLT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) ES(Ongoing) DE(Ongoing) DK(Ongoing) FR(Ongoing) BE(Ongoing) GR(Ongoing) SI(Ongoing) AT(Ongoing) IT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-000954-67"
  },
  {
    "EudraCT Number:": "2015-004726-34",
    "Sponsor Protocol Number:": "SHP620-302",
    "Sponsor Name:": "Takeda Development Center Americas, Inc.",
    "Full Title:": "A Phase 3, multicenter, randomized, double-blind, double-dummy, active-controlled study to assess the efficacy and safety of maribavir compared to valganciclovir for the treatment of cytomegaloviru...",
    "Start Date:": "2017-09-01",
    "Medical condition:": "Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004862, Classification Code: 10021819, Term: Infection in marrow transplant recipients, Level: LLT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "HU(Completed) DE(Completed) GB(GB - no longer in EU/EEA) ES(Ongoing) BE(Completed) CZ(Completed) PL(Completed) FR(Completed) HR(Completed) IT(Ongoing) GR(Completed) AT(Completed) Outside EU/EEA ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2015-004726-34"
  },
  {
    "EudraCT Number:": "2016-004676-22",
    "Sponsor Protocol Number:": "M16-066",
    "Sponsor Name:": "AbbVie Deutschland GmbH & Co. KG",
    "Full Title:": "A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Ulcerative Colitis Who ...",
    "Start Date:": "2019-01-14",
    "Medical condition:": "Ulcerative Colitis",
    "Disease 1:": "Version: 20.0, SOC Term: 10017947 - Gastrointestinal disorders, Classification Code: 10009900, Term: Colitis ulcerative, Level: PT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "BE(Ongoing) SK(Ongoing) AT(Ongoing) ES(Ongoing) SE(Ongoing) NL(Ongoing) DK(Ongoing) GR(Ongoing) PL(Ongoing) DE(Ongoing) LT(Ongoing) PT(Ongoing) GB(GB - no longer in EU/EEA) LV(Ongoing) SI(Ongoing) BG(Ongoing) HR(Ongoing) FR(Not Authorised) IT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004676-22"
  },
  {
    "EudraCT Number:": "2016-004719-10",
    "Sponsor Protocol Number:": "AC-058B303",
    "Sponsor Name:": "Actelion Pharmaceuticals Ltd.",
    "Full Title:": "Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20 mg in subjects with relapsing multiple sclerosis",
    "Start Date:": "2017-10-02",
    "Medical condition:": "relapsing multiple sclerosis",
    "Disease 1:": "Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10063400, Term: Secondary progressive multiple sclerosis, Level: PT",
    "Disease 2:": "Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10063399, Term: Relapsing-remitting multiple sclerosis, Level: PT",
    "Population Age:": "Adults",
    "Gender:": "Male, Female",
    "Trial protocol:": "ES(Ongoing) SE(Completed) PL(Ongoing) CZ(Ongoing) BG(Ongoing) LV(Ongoing) HU(Ongoing) LT(Ongoing) PT(Ongoing) HR(Ongoing) GB(GB - no longer in EU/EEA) FI(Ongoing) GR(Ongoing) RO(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-004719-10"
  },
  {
    "EudraCT Number:": "2019-002621-30",
    "Sponsor Protocol Number:": "M19-063",
    "Sponsor Name:": "AbbVie Deutschland GmbH & Co. KG",
    "Full Title:": "A Randomized, Open Label Phase 3 Study Evaluating Safety and Efficacy of Venetoclax in combination with Azacitidine after allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemi...",
    "Start Date:": "2020-06-10",
    "Medical condition:": "Acute Myeloid Leukemia (AML)",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "GB(GB - no longer in EU/EEA) FR(Ongoing) DE(Ongoing) CZ(Ongoing) ES(Ongoing) IT(Ongoing) HU(Ongoing) GR(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2019-002621-30",
    "Disease:": ""
  },
  {
    "EudraCT Number:": "2016-002154-20",
    "Sponsor Protocol Number:": "CLCZ696G2301",
    "Sponsor Name:": "Novartis Pharma Services AG",
    "Full Title:": "A multi-center, randomized, double-blind, active-controlled, parallel-group Phase 3 study to evaluate the efficacy and safety of LCZ696 compared to ramipril on morbidity and mortality in high risk ...",
    "Start Date:": "2017-03-28",
    "Medical condition:": "Left ventricular dysfunction following an acute myocardial infarction.",
    "Disease 1:": "Version: 20.0, SOC Term: 10007541 - Cardiac disorders, Classification Code: 10000891, Term: Acute myocardial infarction, Level: PT",
    "Population Age:": "Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "DE(Completed) PT(Completed) CZ(Completed) GB(GB - no longer in EU/EEA) GR(Completed) AT(Completed) SK(Completed) NL(Completed) ES(Completed) HU(Completed) BE(Completed) DK(Completed) SE(Completed) FI(Completed) BG(Completed) HR(Completed) IT(Completed) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002154-20"
  },
  {
    "EudraCT Number:": "2017-004703-51",
    "Sponsor Protocol Number:": "COMB157G2399",
    "Sponsor Name:": "Novartis Pharma AG",
    "Full Title:": "An open-label, single arm, multi-center extension study evaluating long-term safety, tolerability and effectiveness of ofatumumab in subjects with relapsing multiple sclerosis ",
    "Start Date:": "2019-01-10",
    "Medical condition:": "Multiple sclerosis",
    "Disease 1:": "Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10048393, Term: Multiple sclerosis relapse, Level: PT",
    "Population Age:": "Adults",
    "Gender:": "Male, Female",
    "Trial protocol:": "DE(Ongoing) SK(Ongoing) HU(Ongoing) GB(GB - no longer in EU/EEA) NL(Ongoing) AT(Ongoing) FR(Ongoing) PT(Ongoing) ES(Ongoing) CZ(Ongoing) SE(Ongoing) LT(Ongoing) DK(Ongoing) FI(Ongoing) BE(Ongoing) LV(Ongoing) GR(Ongoing) HR(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2017-004703-51"
  },
  {
    "EudraCT Number:": "2016-000674-38",
    "Sponsor Protocol Number:": "M14-533",
    "Sponsor Name:": "AbbVie Deutschland GmbH & Co. KG",
    "Full Title:": "A Phase 3 Multicenter, Long-Term Extension Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) in Subjects with Ulcerative Colitis (UC)",
    "Start Date:": "2016-09-20",
    "Medical condition:": "Ulcerative Colitis",
    "Disease 1:": "Version: 20.0, SOC Term: 10017947 - Gastrointestinal disorders, Classification Code: 10009900, Term: Colitis ulcerative, Level: PT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "SK(Ongoing) NL(Ongoing) CZ(Ongoing) AT(Ongoing) FI(Ongoing) PL(Ongoing) SE(Completed) GB(GB - no longer in EU/EEA) DE(Ongoing) LV(Ongoing) GR(Ongoing) EE(Ongoing) IE(Ongoing) HU(Ongoing) PT(Ongoing) LT(Ongoing) BE(Ongoing) NO(Ongoing) ES(Ongoing) HR(Ongoing) IT(Ongoing) RO(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-000674-38"
  },
  {
    "EudraCT Number:": "2016-002937-31",
    "Sponsor Protocol Number:": "MA30143",
    "Sponsor Name:": "F. Hoffmann-La Roche Ltd",
    "Full Title:": "An Open-Label, single-arm study to evaluate the effectiveness and safety of Ocrelizumab in patients with early stage relapsing remitting multiple sclerosis ",
    "Start Date:": "2017-09-12",
    "Medical condition:": "Relapsing remitting multiple sclerosis (RRMS)",
    "Disease 1:": "Version: 20.1, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10028245, Term: Multiple sclerosis, Level: PT",
    "Disease 2:": "Version: 21.1, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10063399, Term: Relapsing-remitting multiple sclerosis, Level: PT",
    "Disease 3:": "Version: 20.0, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10048393, Term: Multiple sclerosis relapse, Level: PT",
    "Disease 4:": "Version: 20.1, SOC Term: 10029205 - Nervous system disorders, Classification Code: 10039720, Term: Sclerosis multiple, Level: LLT",
    "Population Age:": "Adults",
    "Gender:": "Male, Female",
    "Trial protocol:": "NO(Ongoing) SE(Ongoing) AT(Completed) DK(Completed) DE(Ongoing) PT(Ongoing) BE(Ongoing) HU(Ongoing) PL(Ongoing) SK(Ongoing) ES(Ongoing) BG(Ongoing) SI(Ongoing) NL(Ongoing) GB(GB - no longer in EU/EEA) FR(Ongoing) HR(Ongoing) IT(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-002937-31"
  },
  {
    "EudraCT Number:": "2016-003191-50",
    "Sponsor Protocol Number:": "M16-000",
    "Sponsor Name:": "AbbVie Deutschland GmbH & Co. KG",
    "Full Title:": "A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease",
    "Start Date:": "2017-08-23",
    "Medical condition:": "Crohn's disease",
    "Disease 1:": "Version: 20.0, SOC Term: 100000004856, Classification Code: 10013099, Term: Disease Crohns, Level: LLT",
    "Population Age:": "Adolescents, Under 18, Adults, Elderly",
    "Gender:": "Male, Female",
    "Trial protocol:": "SK(Ongoing) DK(Ongoing) DE(Ongoing) PT(Ongoing) CZ(Ongoing) GB(GB - no longer in EU/EEA) LV(Ongoing) IE(Ongoing) BG(Ongoing) AT(Ongoing) PL(Ongoing) NL(Ongoing) EE(Ongoing) SE(Ongoing) ES(Ongoing) GR(Ongoing) NO(Ongoing) LT(Ongoing) BE(Ongoing) HR(Ongoing) FR(Ongoing) IT(Ongoing) RO(Ongoing) ",
    "Link:": "https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2016-003191-50"
  }
]